Tag Archives: Xenex Disinfection Services

C. difficile, a leading Healthcare-Associated Infection, Brings Together World Topic Experts At the International Raising C. diff. Awareness Conference and Health EXPO in Boston, MA on November 9th

 2015 International Raising C. diff. Awareness Conference & Health EXPO

Boston, MA, USA   ~    November 9th

7:30 a.m – 5:00 p.m

conferencesanjuanprJoin us at our 3rd annual International Raising C. diff. Awareness Conference and Health EXPO on November 9th.  Not just another educational conference but one that pairs
world-renowned topic experts with presentations on state-of-the-art health care topics pertaining to a leading Healthcare-Associated Infection (HAI); C. difficile

*Prevention
*Treatments
*Research
*Prevention and Treatment Clinical trials and studies
*Microbiome research
*Infection Prevention
*Environmental Safety
*Fecal Microbiota Restoration and Transplants
……………………..and much more.

The panel of world-renowned topic experts will also discuss the burden of C. diff. the risk factors pertaining to current and emerging treatment options along with the importance of applying evidence-based clinical approaches to the prevention of  a C. diff. infection (CDI), one of the leading Hospital-Acquired Infections.

Clostridium difficile (also known as C. diff.) is an important cause of infectious disease death in the United States.  Nearly half a million Americans suffered from Clostridium difficile (C. diff.) infections in a single year according to a study released February 25, 2015 by the Centers for Disease Control and Prevention (CDC). • More than 100,000 of these infections developed among residents of U.S. nursing homes alone.*  Approximately 29,000 patients died within 30 days of the initial diagnosis of a C. diff. infection.   Of these 29,000 – 15,000 deaths were estimated to be directly related to a  C. diff. infection. Therefore; C. diff. is an important cause of infectious disease death in the U.S.  (Source: CDC)

♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦

Conference Venue:

Double Tree Suites Hotel – Boston – Cambridge
400 Soldiers Field Road, Boston, MA  02134  USA
1-617-783-0090 For Hotel Accommodations *   * There are hotel accommodations available for Sunday evening offered at a special event rate for guests of the C Diff Foundation.  Please inform the DoubleTree representative at the time of creating a reservation to receive the special event room rate.

Exclusive Admission:   $75.00

Student Admission:     $50.00

Each exclusive and student ticket includes admission to all presentations, formal and informal Q&A sessions, introductions to fellow healthcare professionals, continental breakfast  (7:30 a.m.) , a plated four course luncheon with the choice of Chicken Florentine or Petite Filet Mignon main entree, Access to the Health EXPO, a conference book, a educational DVD, and formal conference program.  

To Register and obtain tickets, please click on the following link

NOTE:  *Presentations should not be recorded audio or video or published without prior written and signed permission from the guest speaker and addressed by each attendee seeking publication of said presentations.

♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦♦

Guest Speakers

Key Speaker and Conference Chair:  Professor Mark Wilcox;  Professor of Medical Microbiology, Leeds Institute of Biomedical and Clinical Sciences, UK. Professor Mark Wilcox is a Consultant Microbiologist, Head of Microbiology and Academic Lead of Pathology at the Leeds Teaching Hospitals, Professor of Medical Microbiology at the University of Leeds, and is the Lead on Clostridium difficile for the Public Health England. He has formerly been the Director of Infection Prevention, Infection Control Doctor and Clinical Director of Pathology at Leeds Teaching Hospitals.

Dr. John Bartlett, MD; Assistant Professor Medicine, UCLA/Sepulveda Veterans Admin Hospital 1972-5, Associate Professor and Professor of Medicine, Tufts University School of Medicine, Boston, 1975-80, Professor of Medicine and Chair Division of Infectious Diseases Division, Johns Hopkins University School of Medicine 1980 – 2006; Professor of Medicine, 2006 – 13; Professor of Medicine emeritus, Johns Hopkins University School of Medicine, 2013.Dominant research interests: anaerobic infections and pulmonary infections 1968 – 74; community acquired pneumonia and diagnostic methods, 1974-1980; Bowel prep for elective colon surgery; Protected bronchoscopy brush catheter-1977; Clostridium difficile 1977 – 84, HIV 1983 – 2014; bioterrorism 1999 –2004; Clostridium difficile infection, HIV/AIDS and antibiotic resistance 2006-2013 with  Major current interests: Clostridium difficile infection, HIV infection, antibiotic resistance, careers in infectious diseases.
Presentation Topic: “The discovery of Clostridium difficile as the cause of antibiotic-associated colitis.”

Professor Simon M. Cutting, Professor of Molecular Microbiology at Royal Holloway, University of London is a bacterial geneticist with over 25 years of experience with Bacillus since graduating from Oxford University with a D. Phil in 1986. His D.Phil was on understanding the genetic control of spore formation in Bacillus. After spending 7 years in the renowned laboratory of Professor Richard Losick at Harvard University Biological Laboratories (USA) he spent 3 years as an Assistant Professor at the University of Pennsylvania Medical School in Philadelphia. He returned to the UK in 1996 and since then has worked on developing bacterial spores as novel oral vaccines at
Royal Holloway, University of London. The Cutting lab has developed a number of prototype oral vaccines and is now entering a ‘first in man’ phase 1/IIa clinical trial of a prototype oral vaccine to 
Clostridium difficile (see www.cdvax.org). His other expertise is in the use of Bacillus spores as probiotics and has a number of contracts and consultancies with European and US companies in the food and feed sectors 
(see SporeGen.com).
Presentation Topic: “Mucosal Vaccination: Decolonisation is Essential to Full Protection Against C. difficile

Dr. Sadeq A. Quraishi, MD, MHA, MMSc   Anesthesiologist/Intensive Care physician in the Department of Anesthesia, Critical Care and Pain Medicine at the Massachusetts General Hospital in Boston, MA. He is also Assistant Professor of Anaesthesia at Harvard Medical School in Boston, MA. Dr. Quraishi’s overall research goal is to better define how macro- and micro-nutrient status influence outcomes during acute stress and critical illness. In particular, his research group has focused on the immunomodulatory effects of vitamin D in the perioperative setting, during acute care hospitalization, and for patients in the intensive care unit. Recently, Dr. Quraishi’s group has identified vitamin D status as a potentially modifiable risk factor for hospital acquired C. diff infections and that the severity of C. Diff infections may also be related to vitamin D status .
Presentation Topic:  “Vitamin D as nutritional immunomodulation
for Clostridium difficile infections.”

Dr. Mary Beth Dorr , Phd, studied Pharmacy at the University of the Sciences in Philadelphia and received a PhD in pharmacokinetics and drug metabolism from the University of North Carolina. For the last 28 years Dr. Dorr has worked in the pharmaceutical industry in various capacities, with the majority of the time devoted to the design and implementation of Phase 1 to 4 clinical trials, primarily for anti-infective products.  Prior to joining Merck, Dr. Dorr directed several large, international clinical studies of the efficacy and safety of two IV antibiotics, Synercid and dalbavancin.  She also directed clinical research programs for gastrointestinal and women’s health products.  Mary Beth joined Merck in February 2011 and is currently a Clinical Director in the Late Stage Clinical Development Department as the Clinical Monitor directing 2 large pivotal Phase 3 trials investigating the safety and efficacy of the monoclonal antibodies actoxumab and bezlotoxumab as adjunctive therapy for the prevention of C. difficile recurrence.
Presentation Topic: Bezlotoxumab for Prevention of Recurrent C. difficile Infection in Patients on Standard of Care Antibiotics:  Results of Phase 3 Trials (MODIFY I and MODIFY II)

Dr. Hudson Garrett, Jr., PhD, MSN, MPH, FNP, CSRN, VA-BC, CDONA,FACONA,DON-CLTC
Dr. Hudson Garrett is currently employed as the VP, Clinical Affairs for PDI and NIce-Pak, and is responsible for the global Clinical Affairs program and also the Medical Science Liaison program for all divisions within the company. He holds a Bachelor of Science degree in Biology/Chemistry and Nursing, a dual Masters in Nursing and Public Health, Post-Masters Certificate as a Family Nurse Practitioner, a Post-Masters Certificate in Infection Prevention and Infection Control and a PhD in Healthcare Administration and Policy. He has completed the Johns Hopkins Fellows Program in Hospital Epidemiology and Infection Control, and the CDC Fundamentals of Healthcare Epidemiology program, and is board certified in family practice, critical care, vascular assess, moderate sedation, legal nurse consulting, and a director of nursing in long term care.  Dr. Garrett is also a Fellow in the Academy of National Associations of Directors of Nursing Administration in Long Term Care.
Presentation Topic:  Preventing Clostridium difficile thru Antibiotic Stewardship

Dr. David Cook, PhD;  A scientist and entrepreneur who has held senior operating and management positions in the biotechnology industry over his 20-year career. Before joining Seres Therapeutics, he was the chief operating officer for the International AIDS Vaccine Initiative, a global R&D organization whose mission is to develop a safe, globally accessible vaccine for HIV. Prior to IAVI, David was the founding CEO at Anza Therapeutics, a biotechnology start-up developing a novel microbial vaccine platform to induce cellular immune responses to fight or prevent diseases such as cancer, hepatitis C, malaria and tuberculosis. He is also a co-inventor on over twenty-five patents. He received his undergraduate degree from Harvard College and his PhD in chemistry from the University of California, Berkeley. Dr Cook is presently Executive Vice President of R&D, Chief Scientific Officer with Seres Therapeutics, Inc.. Presentation Topic: “The role of the microbiome in resisting
C. difficile infection and the mechanism of Ecobiotic drugs.”

Julie Gubb, PhD, CIC,   has worked in the field of Infection Prevention in varying roles at healthcare facilities in multiple states for more than two decades. After graduating from the University of Detroit Mercy with a degree in Medical Technology, she began her career as Senior Clinical Microbiologist at an acute care hospital in Detroit, Michigan, where she developed an interest in Infection Control while managing the activities of a full-service microbiology laboratory. She was the Director of Infection Control at Mount Clemens Regional Medical Center in Michigan, and has also held positions in Infection Prevention at healthcare facilities in California and Nevada. As a Senior Infection Preventionist for Xenex, Julie works closely with hospitals throughout the United States to understand their infection prevention goals and develop strategies for attaining those goals. As an active member of the national organization Association for Professionals in Infection Control & Epidemiology (APIC), she has maintained Board Certification in Infection Control and Epidemiology since 1993 and speaks frequently at APIC chapter meetings.
Presentation Topic: Stand Up for Cleanliness / Enhanced Room Disinfection

Dr. Patricia J. Freda Pietrobon, PhD: Associate Vice President, R&D,
Sanofi Pasteur, has over 25 years of experience in the Vaccine & Diagnostic industries and more then 20 years in leadership roles focusing on research & development of new vaccines. Patricia began her career in diagnostic assay development with a focus on validation and quality alignment to regulatory requirements and GXPs. Patricia has been with Sanofi Pasteur for over 25 years and has contributed to the development and licensure of new bacterial & viral vaccines for pediatric & adult populations worldwide.

Barley Chironda, Manager of Infection Prevention and Control (IPAC) and Medical Device Reprocessing Device at St. Joseph Health Centre in Toronto, Canada. He is certified in Infection prevention and control (CIC TM) and has worked extensively as an Infection Preventionist. Barely has been an integral to the successful decline in Clostridium difficile infections through implementing innovative technology and quality improvement behavioral changes.   Barley’s presentation will show a behind the scenes account of the C. diff. management from the healthcare facilities perspective while providing a call to action.

Dr. Martha Clokie, PhD, Leicester UK, Professor in Microbiology.  Dr. Cloakie’s research focuses on phages that infect bacterial pathogens of medical relevance and  has published 41 papers in this area. Her major focus has been on Clostridium difficile where she has  isolated a large phage collection. In vitro and in vivo data has shown that the viruses have therapeutic potential. A patent has been filed  on these phages and  working with AmpliPhi to develop a product. Dr. Cloakie  has regular contact with the BBC and other media to talk about her work, and other phage projects, and has consulted with Science museum, London and Eden Project, UK to advise on bacteriophage displays.

Lee Jones, Founder, President and CEO of Rebiotix Inc, has over thirty years of experience in the medical technology industry in large and small companies and academia. Most recently Lee was Chief Administrative Officer of the Schulze Diabetes Institute at the University of Minnesota, Minneapolis, MN and is the former president and chief executive officer of Inlet Medical. Inlet Medical was sold to Cooper Surgical in 2006. Lee will introduce Rebiotix Inc.,  a biotechnology company founded in 2011 in Roseville, MN to revolutionize the treatment of challenging gastrointestinal diseases by harnessing the power of the human microbiome The company is developing an entirely new kind of biological drug designed to reverse pathogenic processes responsible for disease through the transplantation of live human-derived microbes into a sick person’s intestinal tract.
Presentation Topic:  Blazing a Trail with the Gut Microbiome

Professor Nancy Sheridan,   a C. diff. Survivor and  Associate Professor at the Fashion Institute of Technology and a winner of the prestigious SUNY Chancellor’s Award for Excellence in Teaching. Professor Sheridan will share her personal experience being treated for a painful and extended journey with a C. diff. infection (CDI).  Professor Sheridan has been teaching since fall 2000 in the Fashion Merchandising Management Department within the School of Business and Technology. For the past seven years, she has also taught at the University of Pennsylvania, Wharton Business School to undergraduate and MBA students.

Dr Mel Thomson, PhD,  completed her Honors degree in microbiology and immunology at the University of Melbourne . She then immigrated to the UK where she worked on various projects as diverse as allergy and cancer before undertaking further studies. She completed a Masters of Research in functional genomics before reading for a PhD in microbial genetic regulation in Neisseria species, both at University of York, UK. After the award of her PhD, Dr Thomson became interested the host-pathogen interactions at the Leeds Institute of Molecular Medicine, UK.  Dr Thomson returned to Australia in 2011 to start her own research group studying host-pathogen interactions in the GI tract, at Deakin Medical School. A passionate science communicator, and has recently become a national ‘torch bearer’ for the concept of crowd funding academic research, which a track record of three successful ‘Pozible’ crowd funding campaigns, ‘Mighty Maggots’, ‘Hips 4 Hipsters’ and ‘No more Poo Taboo’
Presentation Topic: All that glitters is C.diff awareness gold and Crowdfunding: The ‘No more poo taboo’ animation”

Dr Rahma Wehelie – LifeClean International AB – Sweden; LifeClean International AB is a Swedish company with an international orientation that conducts research, development, and production in the spore, bacteria, and virus eliminating industry. LifeClean was established in 2013 after many years of research and the headquarter lies in Uddevalla, Sweden.
Presentation Topic: Dr Wehelie will be discussing LifeClean’s research, development and production eliminating Clostridium difficile, Norovirus, and other multidrug-resistant bacteria

Dr. Klaus Gottlieb, MD, FACG,Synthetic Biologics, Inc.,Vice President, Clinical;Regulatory Affairs   Dr. Gottlieb is an experienced board-certified internist and gastroenterologist with a strong clinical science, business and drug development background. He joined Synthetic Biologics after serving as Senior Medical Director-Therapeutic Strategy Lead Gastroenterology of Quintiles, a Fortune 500 company and the world’s largest provider of biopharmaceutical development and commercial outsourcing services. At Quintiles, Dr. Gottlieb served as Global Medical Advisor for three separate large Phase 3 inflammatory bowel disease (IBD) trials and provided significant input on the shaping, design and evaluation of numerous IBD and other gastrointestinal (GI) clinical trials throughout all stages of development programs. Prior to joining Quintiles in 2013, he was with the FDA in Silver Spring, MD as a Senior Clinical Reviewer for the Division of Gastroenterology and Inborn Errors Products. Widely published, his academic contributions have been recognized by an appointment as Professor of Medicine (Clinical) at George Washington University and the following elected fellowships: Fellow American College of Physicians, Fellow American College of Gastroenterology, Fellow American Society of Gastrointestinal Endoscopy.  Presentation Topic: Protecting the Gut Microbiome

For additional information contact the C Diff Foundation: (919) 201-1512 or
info@cdifffoundation.org

To Register and obtain tickets, please click on the following link

We would like to sincerely thank the following Exclusive and Supporting Corporate Sponsors for their continued support  and joining the Foundation in
Raising C. diff. Awareness worldwide.

  • Enjoy visiting our Exclusive Corporate Sponsors websites by simply clicking on their logos belowsyntheticbiologics
  • AmericanGreenTechnologyhrmsrebiotixlogo

LIFECLEANLOGO 001Xenex_LogoLockups_PantoneC

uBiome-Logo (2)SporeGen Logo 2

SANOFI_Pasteur_RVBThis conference is supported through an educational grant from Sanofi Pasteur US

 

MERCKBW2015_medLogoBLK [Converted] (2)This activity has been supported by an independent patient
advocacy grant from Merck & Co., Inc.

Children’s Hospital in Los Angeles California Introduces New High-Tech Disinfecting Robots

Xenex_LogoLockups_PantoneC

 

 

Half a million square feet. More than 350 beds. And tomorrow, they clean it all over again. Every day, Environmental Services  staff members work to disinfect every surface in Children’s Hospital Los Angeles, playing a crucial behind-the-scenes role in preventing infections and keeping patients safe. Now, on top of scrubbing, spraying, mopping and wiping, they can add another action – zapping.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150915006821/en/

“Cleaning is a fundamental function of any healthcare facility, and our housekeepers may go unnoticed because their work disinfecting the hospital often happens before patients even get to their rooms,” says Jill Hoffman, MD, a pediatric infectious disease specialist and medical director of infection prevention and control at Children’s Hospital Los Angeles. “We arm our doctors and nurses with high-tech tools and surgical robots, and now we are doing the same for those on the front line of our battle against infections.”

As hospitals across the country look for new, innovative ways to battle pathogens and multi-drug resistant organisms that put patients at risk, and as flu season draws closer, CHLA has introduced four new non-human team members that can annihilate potentially lethal germs and bacteria lurking in hard-to-reach places.

CHLA’s four new Xenex Germ-Zapping Robots™ – affectionately named Charlie, Ziggy, Phoenix and R2Clean2 – use pulsed xenon ultraviolet (UV-C) light, thousands of times more powerful than sunlight, to quickly destroy harmful bacteria, viruses, fungi and even bacterial spores. The portable disinfection system takes about 20 minutes per room – for a total of about an hour when combined with traditional cleaning techniques – and is effective against even the most dangerous pathogens, including Clostridium difficile (C-diff), norovirus, influenza and methicillin-resistant Staphylococcus aureus (MRSA).

Supplementing the work of more than 200 top-notch EVS/housekeeping staff, this new technology gives CHLA another tool to provide hospitalized infants, children and young adults the safest experience possible.

“Adding another layer of protection to our already robust infection prevention protocols allows us to be even more proactive in protecting our patients,” says Hoffman. “Children’s Hospital Los Angeles is nationally and internationally recognized for patient care, and even one hospital-acquired infection is one too many. These robots can help us advance towards our goal of zero infections.”

In fact, during a brief trial run with a Xenex robot earlier this year, CHLA was able to see a 10 percent reduction in infection rates in areas of the hospital tested. Other hospitals that have used the robots for longer periods have reported even more dramatic reductions – more than 50 percent in some cases – in C. diff and MRSA rates.

C Diff Foundation’s “Raising C.diff Awareness” Continuing Education Workshop Launched in Community Colleges

cdiffhandwashingbreakpostercdiffInfControl Healthcare Professionals, employed in all areas of healthcare, attended the first “Raising C. diff. Awareness” Continuing Education class being offered in allied health at the Community Colleges.

Attendees learned about C. difficile prevention, treatments, and environmental safety.

ShelbyTeachingThe class learned how to prevent contamination with the opportunity to practice safe infection control techniques, discuss the physical, psychological, social, and financial impact this infection causes to a patient, families, and healthcare industry and how to prevent infections in their everyday practices.

Congratulations to all the attendees of “Raising C. diff. Awareness” Continuing Education Workshop – Spring Class 2015!  Each attendee learned something new today and each has a voice – Now is the time to take the knowledge and continue raising C. diff. awareness in every area of practice.  Each student joins us in the shared goal~  to witness a decrease in newly diagnosed   C. diff. infections worldwide.

Thank you to all who attended this workshop and it was a pleasure to provide you with valid information for C. diff. prevention, treatments, and environmental safety.

“None of us can do this alone…..all of us can do this together!”

 

CdiffRCDA-2May2015

 

LindaAngelo CdiffRCDA-3May2015 CdiffRCDAgroupMay2015 CdiffRCDA-5May2015 CdiffRCDA-7May2015

Taught by:
Nancy Caralla, Founding Executive Director C Diff Foundation,
Shelby Lassiter, RN, BSN, CPHQ, CIC, Consulting Infection Preventionist for C Diff Foundation
Karen Factor, RD, MBA, Chairperson Nutrition and Wellness C Diff Foundation
Angelo Ortiz, Treasurer, C Diff Foundation
Linda Davis, RN, BSN, Community Nurse for C Diff Foundation

Continuing Education through Durham Community Colleges

Xenex Improving Patient Safety In The Operating Room

Xenexrobot2015

Interest in understanding the role of the operating room (OR) environment in transmission of surgical site infections (SSIs) has increased greatly in recent years. Numerous studies have shown that standard cleaning practices leave significant levels of contamination on OR surfaces and can contribute to SSIs, the most expensive hospital acquired infection (HAI) to treat. Xenex Disinfection Services’ patented pulsed xenon Full Spectrum™ ultraviolet (UV) disinfection technology has been proven to quickly destroy the viruses, bacteria, mold, fungus and bacterial spores in ORs that cause SSIs.

Traditional cleaning practices leave behind dangerous pathogens such as Clostridium difficile (C.diff), methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). A study conducted at Cambridge Health Alliance, a Harvard Medical School Teaching Affiliate, demonstrated that pulsed xenon UV light disinfection can significantly decrease OR contamination. The study showed that Xenex’s germ-zapping robot reduced surface contamination in the OR by 81 percent, and that while between-case contamination in the OR continued to rise from case to case with standard cleaning, it was reduced to almost zero when the Xenex robot was used between cases.

Xenex will demonstrate its germ-zapping robot at the Association of Perioperative Registered Nurses (AORN) Surgical Conference & Expo in Denver, CO, March 7-10, 2015. Hospitals using Xenex for OR disinfection will discuss how they are eliminating the microorganisms that cause infections and make patients and healthcare workers sick.

Xenex has teamed up with AORN to host an educational session as part of the AORN Leadership Development series. On Tuesday, March 10, Julie Tonsager, OR Team Lead at St. Cloud Surgical Center, will share the facility’s two-year journey in evaluating UV technology. She will discuss the steps they took to ensure a successful implementation in their ORs.

“The risk of post-op infection poses a great risk to patients and healthcare facilities alike. We have proven repeatedly that hospitals using our room disinfection technology are reducing patient risk because they are destroying the microorganisms that cause infections. Most importantly, hospitals using our robots are reporting infection rate reductions of more than 50 percent as outcome studies in peer reviewed medical journals,” said Dr. Mark Stibich, Chief Scientific Officer of Xenex. “Unlike other UV disinfection systems, the Xenex robot utilizes pulsed xenon and kills C.diff spores in less than five minutes. The robot’s five-minute disinfection cycle enables it to disinfect areas and rooms quickly so it can be used throughout the entire facility, including multi-bed wards, to enhance patient and healthcare worker safety.”

Uniquely designed for ease of use and portability, a hospital’s environmental services staff can operate the Xenex robot without disrupting hospital operations and without using expensive chemicals. With a five-minute disinfection cycle, the robot has helped disinfect 30-62 hospital rooms per day (according to Xenex customer reports), including patient rooms, operating rooms, equipment rooms, emergency rooms, intensive care units and public areas. More than 250 hospitals, Veterans Affairs and DoD facilities in the U.S. are using Xenex robots, which are also in use in skilled nursing facilities, ambulatory surgery centers and long term acute care facilities.

There are now ten peer reviewed studies confirming the efficacy of the Xenex Germ-Zapping Robot™ in the healthcare environment, including three studies showing a decrease in C.diff, MRSA and MDRO infections when the hospital used the Xenex robot for room disinfection.

About Xenex Disinfection Services

Xenex’s patented pulsed xenon Full Spectrum UV room disinfection system is a pesticidal device used for the advanced cleaning of healthcare facilities. Due to its speed and ease of use, the Xenex system has proven to integrate smoothly into hospital cleaning operations. The Xenex mission is to eliminate harmful bacteria, viruses and spores that can cause hospital acquired infections in the patient environment, and to become the new standard method for disinfection in healthcare facilities worldwide. For more information, visit www.xenex.com.

 

To review in its entirety click on the link below

http://finance.yahoo.com/news/improving-patient-safety-operating-room-203000073.html

Xenex Disinfection Services; UV room disinfection systems

Image

Xenex’s patented pulse xenon UV room disinfection system is a pesticidal device used for the advanced environmental cleaning of healthcare facilities

Xenex Disinfection Services – world leader in pulsed xenon UV room disinfection systems for healthcare facilities. Xenex is in the news and facilities are using Xenex room disinfection systems. Facilities using Xenex room disinfection systems make the 2013 best hospitals list.

Founded in 2008 Xenex has quickly become one of the leaders in the room disinfection industry. In just 5-10 minutes per room, their portable “robot” can eliminate the deadly microorganisms and super-bugs that cause infections. The Xenex patented pulse xenon UV room disinfection system is a pesticidal device for the advanced environmental cleaning of healthcare facilities. The Xenex system has been repeatedly shown to integrate smoothly into hospital cleaning operations because of its speed and ease of use.

Healthcare associated infections (HAIs) are responsible for the deaths of nearly 300 people per day in the USA. Hospital disinfecting and environmental cleaning has become priority in controlling the spread of HAIs (i.e., C. diff., MRSA, Carbapenem-Resistant Enterobacteriaceae (CRE), Acinetobacter baumannii, etc.,).

The Xenex mission is to eliminate bacteria, viruses, and spores in the patient environment that causes HAIs and to become the new standard method for disinfection in healthcare facilities worldwide.

(finance.yahoo.com/news/xenex-changes-name-xenex-disinfection-132400810.html)

For Additional information and positive news regarding Xenex Disinfection Services please click on the following links provided:

http://www.xenex.com/xenex-robot/

http://www.xenex.com/why-xenex/how-uv-disinfection-works/

http://www.businesswire.com/news/home/20130802005827/en/Xenex%E2%80%99s-Germ-zapping-Robot-Enhancing-Patient-Safety-Decatur

http://finance.yahoo.com/news/xenex-superbug-zapping-robot-eliminates-143600083.html